# India Theranostics Market

> India Theranostics Market Research Report By Application (Oncology, Neurology, Cardiology, Infectious Diseases), By Technology (Genomics, Proteomics, Metabolomics, Biomarkers), By End User (Hospitals, Diagnostic Laboratories, Research Institutes) and By Product Type (Instruments, Reagents, Software) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.77%
- **2024:** $ 367.04 Million
- **2025:** $ 410.24 Million
- **2035:** $ 1,248.28 Million
- **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Bristol-Myers Squibb (US), Merck KGaA (DE), Illumina (US), Qiagen (NL), Genomic Health (US)

**Report ID:** MRFR/HC/43898-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-theranostics-market-45578

---

## Market Summary

## **India Theranostics Market Overview**

As per MRFR analysis, the India Theranostics Market Size was estimated at 410.5 (USD Million) in 2023.The India Theranostics Market is expected to grow from 514.0(USD Million) in 2024 to 1,767.0 (USD Million) by 2035. The India Theranostics Market CAGR (growth rate) is expected to be around 11.88% during the forecast period (2025 - 2035).

### **Key India Theranostics Market Trends Highlighted**

The market for theranostics in India is expanding significantly due to a number of important factors. The need for individualized treatment is being driven by the rising incidence of chronic illnesses and rising healthcare costs. There is a tremendous drive to include theranostics into traditional therapy paths as the Indian government concentrates on enhancing healthcare infrastructure and encouraging cutting-edge diagnostic procedures.

Initiatives like the National Health Mission, which seeks to increase access to high-quality healthcare, reflect this and make theranostics more attractive to both patients and healthcare professionals. The creation of customized treatments based on genetic profiles is one area of opportunity to be investigated in the Indian market. Research and development projects that make use of genetic testing and biomarker identification are also gaining popularity since they have the potential to greatly improve illness management.

Working together, academic institutions, pharmaceutical firms, and diagnostic labs can produce novel theranostics solutions that will increase their market share overall. As awareness campaigns and training initiatives concerning customized medicine gain traction, recent trends show that healthcare professionals are gradually coming to accept theranostics. Indian patients are increasingly looking for focused medicines that provide better results as they gain more knowledge about their treatment alternatives. Beyond this, technological developments are opening the door to more effective theranostic solutions, such as the application of artificial intelligence in diagnostics.

The India Theranostics Market is anticipated to grow as these trends continue to develop, supporting a more comprehensive and patient-centered approach to healthcare.

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **India Theranostics Market Drivers**

### **Rising Incidence of Cancer in India**

The India Theranostics Market is significantly driven by the rising incidence of cancer within the country. According to the National Cancer Registry of India, there were an estimated 1.16 million new cancer cases reported in 2023, reflecting a general rise in cancer diagnoses.

The increasing burden of cancer is leading to heightened demand for advanced diagnostics and targeted therapies, which are the key components of theranostics. The Indian government has initiated several awareness and prevention campaigns supported by organizations like the Indian Council of Medical Research (ICMR), which indicate a strong commitment to addressing this public health challenge.

As more patients seek personalized treatment options, the demand for theranostic products is anticipated to grow, contributing to the overall market expansion. Furthermore, the National Health Mission has been focusing on improving cancer treatment facilities and accessibility, enhancing the scope for theranostics in healthcare.

### **Advances in Biomarker Discovery**

Advancements in biomarker discovery are propelling the growth of the India Theranostics Market. Significant investments in research and development by Indian biotech firms have led to the identification of novel biomarkers for various diseases. Institutions such as the Indian Institute of Science and several local universities are at the forefront of this research.

The identification of these biomarkers facilitates the development of personalized medicine solutions, which aligns with the global trend of tailored therapeutic strategies.

For instance, the Indian government has provided substantial funding through initiatives like the Atal Innovation Mission, encouraging innovation in healthcare sectors, including theranostics. This stimulates a conducive ecosystem for biotech firms to innovate and commercialize new theranostic tests, thereby augmenting market growth.

### **Growing Pharmaceutical and Biotech Industry**

India's robust pharmaceutical and biotech industry significantly impacts the growth of the India Theranostics Market. India is one of the world's largest producers of generics and has a rapidly expanding biotechnology sector driven by government initiatives and favorable policies.

The Biotechnology Industry Research Assistance Council (BIRAC) has supported numerous startups and established companies in developing biotherapeutics and diagnostics.

This growth fosters collaborative research efforts that focus on integrating theranostics into routine clinical practices, thus elevating market prospects. Furthermore, the Make in India initiative aims to promote local manufacturing and innovation in biotechnology, actively promoting the development of health technologies that include theranostic capabilities.

### **Increase in Government Initiatives for Healthcare Improvement**

The India Theranostics Market is further bolstered by an increase in government initiatives aimed at improving healthcare standards. The National Health Policy of 2017 emphasizes access to affordable and high-quality healthcare, including cancer care.

Initiatives such as Ayushman Bharat, which aims to provide healthcare coverage to millions of underserved individuals, also underline the government’s commitment to enhancing healthcare services. Supported by organizations like the Quality Council of India, these measures create a more conducive environment for the implementation and adoption of theranostic technologies in the healthcare system.

The focus on enhancing infrastructure and availability of advanced diagnostics directly correlates with the increasing adoption of theranostics, setting a solid foundation for market growth.

## **India Theranostics Market Segment Insights**

### **Theranostics Market Application Insights**

The India Theranostics Market exhibits significant prospects across various applications as it evolves from 2019 to 2032, offering valuable insights into market dynamics. The multi-faceted nature of this sector is reflected in its segmentation into areas such as Oncology, Neurology, Cardiology, and Infectious Diseases, each playing a pivotal role in shaping the future of personalized medicine in India. Oncology stands at the forefront, reflecting the growing burden of cancer in India, which has seen an increase in incidences due to lifestyle changes and environmental factors.

Consequently, theranostic applications in oncology facilitate more targeted therapies and improve treatment outcomes through personalized insights into patient-specific cancer profiles, making it a priority area of healthcare investment in the country. Neurology is gaining traction as well, especially with rising neurological disorders associated with aging populations and lifestyle factors. Theranostics in this segment enable the development of precision therapies for conditions such as Alzheimer’s and Parkinson’s diseases, thus suggesting that this area will gain substantial attention in research and clinical applications throughout the anticipated growth period.

Cardiology also plays a significant role, as cardiovascular diseases are a leading cause of mortality in India. The rising prevalence necessitates the need for innovative solutions that can provide tailored treatment options based on individual risk profiles and disease progression. This segment presents opportunities for advancements in predictive analytics, thereby enhancing patient care. Infectious Diseases, particularly in the wake of recent global health events, have underscored the value of theranostics in diagnosing and treating various infections more efficiently.

The integration of diagnostic and therapeutic strategies in this area allows for more robust management of diseases such as tuberculosis and viral infections, which remain prevalent in the Indian healthcare landscape. Together, these application areas not only highlight the growth drivers but also provide a framework for addressing challenges in healthcare delivery in India. The unique demographics, prevalence rates of diverse diseases, and increased government focus on healthcare improvements create a conducive environment for market expansion across these application segments.

The ongoing advancements in technology and a growing emphasis on personalized medicine signal promising growth trajectories for the India Theranostics Market, poised to improve patient outcomes effectively while also addressing the relevant healthcare challenges in the region.  Overall, the application segmentation within the India Theranostics Market reflects an evolving landscape that resonates with both present needs and future growth potential in personalized healthcare.

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Theranostics Market Technology Insights**

The India Theranostics Market is experiencing notable developments within the Technology segment, driven by advancements in Genomics, Proteomics, Metabolomics, and Biomarkers. Genomics plays a pivotal role in personalizing treatment strategies, as it allows for the analysis of individual genetic information, ensuring tailored therapies that increase the efficacy of treatments.

Proteomics offers insights into protein expressions and interactions that are critical for understanding disease mechanisms, thus facilitating the discovery of potential therapeutic targets. Metabolomics, which focuses on the comprehensive analysis of metabolites, aids in the identification of disease biomarkers, further enhancing the precision of Theranostics.

Biomarkers serve as essential tools in diagnostic and therapeutic applications, enabling early disease detection and monitoring treatment responses. The combination of these technologies is integral to the evolution of precision medicine in India, catering to the growing demand for more effective and personalized healthcare solutions.

Furthermore, government initiatives and investments in healthcare infrastructure are bolstering research and development across these domains, promising significant growth in the India Theranostics Market and its various segments.

### **Theranostics Market End User Insights**

The India Theranostics Market, specifically focusing on the End User segment, reveals a diverse landscape comprising key players such as hospitals, diagnostic laboratories, and research institutes. Hospitals are crucial, as they not only offer patient treatment but also play a significant role in utilizing advanced therapeutic and diagnostic technology, thereby driving innovative approaches to patient care. Diagnostic laboratories are essential in this ecosystem, as they perform critical tests that facilitate timely and accurate diagnoses, making them indispensable in the theranostics workflow.

Research institutes contribute significantly by advancing scientific knowledge, developing new theranostic agents, and conducting clinical trials that pave the way for new treatment methodologies. As the demand for personalized medicine continues to rise in India, the integration of theranostic solutions within these end-users is expected to enhance patient outcomes and optimize healthcare efficiency.

The growing emphasis on precision medicine, supported by governmental initiatives to bolster healthcare infrastructure, presents substantial opportunities for the India Theranostics Market, demonstrating robust growth potential over the coming years. The segmentation across these crucial sectors highlights the importance of a collaborative approach to improve health outcomes and foster advancements in theranostics.

### **Theranostics Market Product Type Insights**

The India Theranostics Market is anticipated to experience significant growth, particularly in the Product Type segment encompassing Instruments, Reagents, and Software. Instruments are vital as they play a key role in the precision diagnostics and targeted treatments that define theranostics, facilitating tailored patient management.

Reagents also hold a crucial position, serving as the essential biochemical components needed for diagnostic testing and therapeutic applications, thereby influencing treatment decisions effectively. Furthermore, Software contributes immensely by enabling data analysis and interpretation, which aids healthcare professionals in making informed decisions based on complex patient data sets.

The growth in the India Theranostics Market is supported by advancements in biotechnology and a rising emphasis on personalized medicine. Additionally, initiatives by the Indian government to improve healthcare infrastructure and facilitate research in theranostics create a favorable environment for the expansion of this market sector.

## **India Theranostics Market Key Players and Competitive Insights**

The India Theranostics Market is evolving rapidly as a result of advancements in personalized medicine and the increasing demand for targeted therapies. This market segment integrates therapeutic and diagnostic capabilities to tailor treatments to individual patients' needs. With a significant investment in research and development, key players are aiming to enhance precision medicine by uncovering more specific biomarkers for various diseases, particularly in oncology. The competitive landscape is characterized by collaborations between pharmaceutical and diagnostic companies, fostering innovative solutions that address the unique health challenges faced in India.

This dynamic market is witnessing an influx of both domestic and international firms striving to carve out a niche, resulting in a diverse portfolio of products and services that cater to the growing health care requirements of the region. Qiagen has established a robust presence in the India Theranostics Market, leveraging its cutting-edge technologies and expertise in molecular diagnostics. The company's strengths lie in its comprehensive range of products designed for various applications in cancer diagnostics as well as infectious diseases, enabling healthcare providers to make informed treatment decisions.

Qiagen boasts a strong portfolio of innovative assays and platforms to assist in the development of personalized therapies, demonstrating its commitment to enhancing patient outcomes through precision medicine. With a solid reputation for quality and reliability, Qiagen is actively expanding its partnerships and collaborations within the country, aiming to further its reach and enhance the accessibility of its advanced diagnostic solutions in the Indian healthcare landscape.

Bristol-Myers Squibb holds a significant role in the India Theranostics Market, particularly with its portfolio of therapeutics that include several oncology treatments known for their targeted mechanisms. The company continues to strengthen its market presence through strategic mergers and acquisitions, enhancing its research capabilities and expanding its offerings in personalized therapies. Bristol-Myers Squibb's key products in the Indian market largely focus on immuno-oncology, which not only revolutionizes cancer treatment but also integrates diagnostic solutions tailored for patient stratification.

The company maintains a strong commitment to innovation, and its proactive approach to partnerships with local research institutions further augments its ability to deliver advanced therapeutic options to the Indian population. Bristol-Myers Squibb's emphasis on collaboration and adaptation to the regional healthcare needs positions it as a prominent player in the competitive landscape of theranostics in India.

### **Key Companies in the India Theranostics Market Include**

### **India Theranostics Market Developments**

The India Theranostics Market has witnessed significant developments, particularly after the COVID-19 pandemic accelerated the demand for personalized medicine and advanced diagnostics. Companies like Roche and Thermo Fisher Scientific are heavily investing in research to develop innovative diagnostics solutions tailored to Indian healthcare needs.

In terms of mergers and acquisitions, there was a notable announcement in September 2023 when Merck & Co. acquired a local biotech firm to expand its capabilities in precision medicine. Similarly, in August 2023, Siemens Healthineers announced a partnership with local hospitals to enhance molecular imaging services, targeting the cancer diagnostic segment.

The market's valuation has been robust, with government initiatives promoting home-grown biopharma innovation, which has been aided by pharmaceutical giants like Pfizer and Novartis expanding their R&D footprints in India. Recent regulatory changes are aimed at fast-tracking approvals for new theranostics products, promoting quicker access to advanced therapies for patients.

## **India Theranostics Market Segmentation Insights**

## Market Drivers

### Advancements in Biotechnology

Technological advancements in biotechnology are significantly influencing the theranostics market in India. Innovations in genomics, proteomics, and molecular diagnostics are enabling the development of more precise and effective theranostic products. For instance, the introduction of next-generation sequencing (NGS) technologies has revolutionized the ability to identify genetic markers associated with various diseases. This has led to the creation of targeted therapies that are tailored to individual patient profiles. As a result, the market is witnessing a surge in the availability of personalized treatment options, which are expected to grow at a CAGR of around 15% over the next five years. Such advancements are likely to enhance the efficacy of treatments and improve patient adherence, thereby driving the theranostics market forward.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases in India, such as diabetes, cancer, and cardiovascular disorders, is a primary driver for the theranostics market. As of 2025, it is estimated that chronic diseases account for approximately 60% of all deaths in the country. This alarming trend necessitates advanced diagnostic and therapeutic solutions, which theranostics provides. The integration of diagnostics with therapeutics allows for tailored treatment plans, enhancing patient outcomes. Consequently, healthcare providers are increasingly adopting theranostic approaches to manage these diseases effectively. The growing burden of chronic conditions is likely to propel the demand for innovative theranostic solutions, thereby expanding the market significantly.

### Regulatory Support for Innovative Therapies

Regulatory bodies in India are increasingly supporting the development and approval of innovative theranostic products. The Central Drugs Standard Control Organization (CDSCO) has streamlined the approval process for new diagnostic and therapeutic agents, which is likely to encourage more companies to invest in theranostics. This supportive regulatory environment is essential for fostering innovation and ensuring that new therapies reach the market efficiently. As a result, the theranostics market is expected to benefit from a more favorable landscape for product development and commercialization. The anticipated growth in the number of approved theranostic products could lead to a market expansion of approximately 25% over the next few years, reflecting the positive impact of regulatory support.

### Growing Investment in Healthcare Infrastructure

The Indian government is increasingly investing in healthcare infrastructure, which is a crucial driver for the theranostics market. Initiatives aimed at enhancing healthcare facilities, particularly in rural areas, are expected to improve access to advanced diagnostic and therapeutic services. The National Health Mission and various state-level programs are allocating substantial funds to upgrade healthcare systems. This investment is likely to facilitate the integration of theranostic technologies into routine clinical practice. As healthcare facilities become more equipped with modern diagnostic tools, the adoption of theranostics is expected to rise, potentially increasing market growth by 20% over the next few years. Enhanced infrastructure will not only improve patient outcomes but also foster innovation in the theranostics sector.

### Rising Awareness Among Healthcare Professionals

There is a notable increase in awareness among healthcare professionals regarding the benefits of theranostics in India. Medical practitioners are becoming more educated about the potential of combining diagnostics with therapeutics to enhance treatment efficacy. This growing knowledge is likely to lead to a shift in clinical practices, with more healthcare providers opting for theranostic approaches in patient management. Educational programs and workshops focusing on the importance of personalized medicine are being organized, which further promotes the adoption of theranostics. As healthcare professionals recognize the value of these integrated solutions, the theranostics market is expected to experience substantial growth, potentially increasing by 18% in the coming years.

## Future Outlook

The [Theranostics Market](https://www.marketresearchfuture.com/reports/theranostics-market-8057) in India is projected to grow at 11.77% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased R&D investments, and rising healthcare demands.

**New opportunities:**

- Development of AI-driven diagnostic tools for personalized treatment plans.
- Expansion of telemedicine platforms integrating theranostic solutions.
- Partnerships with biotech firms for innovative biomarker discovery.

By 2035, the theranostics market is expected to achieve substantial growth, positioning itself as a leader in personalized healthcare.

## Segment Insights

### By Application: Oncology (Largest) vs. Neurology (Fastest-Growing)

The India theranostics market is characterized by diverse applications, with oncology holding the largest market share. This segment benefits from increasing cancer prevalence and is supported by advancements in personalized medicine that enhance treatment accuracy. Neurology follows as a fast-growing segment, driven by the rising incidence of neurological disorders and the expanding focus on early diagnosis and targeted therapies, making it a key area for future investments and innovations.

Growth trends in the theranostics market show a significant shift towards personalized medicine, with both oncology and neurology leading the way. The demand for more effective and tailored therapeutic options is propelling research and development in these areas. Furthermore, increasing healthcare expenditure and technological advancements in diagnostic tools are acting as strong drivers for growth, making these segments crucial targets for market players seeking expansion in the India theranostics market.

Oncology (Dominant) vs. Cardiology (Emerging)

Oncology remains the dominant segment in the India theranostics market, characterized by a robust framework for cancer diagnostics and treatment that integrates innovative biotechnologies. This segment is characterized by a wide range of applications, from early detection to monitoring of treatment responses, which significantly enhance patient outcomes. In contrast, cardiology is emerging as a vital segment, focusing on cardiovascular diseases, which are increasingly prevalent in the Indian population. With ongoing innovations in theranostic approaches tailored for heart conditions, cardiology holds promising growth potential, supported by advancements in imaging technologies and biomarker research, thereby establishing a strong foothold alongside oncology in the evolving landscape of theranostics.

### By Technology: Genomics (Largest) vs. Proteomics (Fastest-Growing)

In the India theranostics market, the technology segment is dominated by genomics, which captures the largest market share due to its extensive applications in personalized medicine and cancer treatment. Following closely is proteomics, which, while smaller in market share, is gaining significant traction as advancements in protein analysis technologies accelerate its adoption in clinical diagnostics.

The growth trends in the technology segment reveal a robust shift towards emerging technologies like metabolomics and biomarkers, which are increasingly being integrated into theranostic approaches. Factors driving this growth include rising investments in research and development, greater emphasis on precision medicine, and the growing awareness of the importance of early diagnosis and targeted therapies. The convergence of these technologies is setting the stage for innovative diagnostic solutions that enhance patient outcomes.

Genomics: Dominant vs. Proteomics: Emerging

Genomics is currently the dominant technology in the India theranostics market, characterized by its foundational role in understanding genetic variations and personalizing treatment plans for patients. The increasing prevalence of genetic disorders and the need for tailored therapies have propelled genomics to the forefront of theranostic applications. On the other hand, proteomics is an emerging technology that focuses on the large-scale study of proteins and their functions. As new techniques for protein analysis are developed, proteomics is rapidly becoming vital in biomarker discovery and the development of targeted therapies. Together, these technologies are transforming the diagnostics landscape, enhancing the precision and efficacy of therapeutic interventions.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

The distribution of the end-user segment in the India theranostics market reveals that hospitals hold the largest market share, driven by their central role in patient care and diagnostic processes. With a higher patient influx and a diverse range of theranostic applications, hospitals are key players in the segment. On the other hand, diagnostic laboratories are increasingly gaining traction, supported by advancements in diagnostic technologies and a growing emphasis on personalized medicine.

Growth trends in this segment are influenced by several factors, including an increasing demand for accurate and timely diagnostics, along with a rise in chronic diseases necessitating comprehensive testing. The integration of innovative theranostic solutions in clinical settings is propelling the expansion of diagnostic laboratories, as they adapt to advanced diagnostic methodologies. Furthermore, investments in research and development are fueling growth in research institutes, contributing to more profound insights into theranostic applications.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals represent the dominant end-user segment in the India theranostics market due to their extensive facilities and capacities to handle complex diagnostic interventions. They are well-equipped with cutting-edge technologies and are prioritized by patients for comprehensive healthcare services, making them a preferred point for theranostic applications. In contrast, diagnostic laboratories are emerging, characterized by specialized services focusing on molecular diagnostics and genetic testing. Their growth is propelled by enhanced operational capabilities, partnerships with healthcare providers, and increasing demand for precise diagnostic tools. As both segments evolve, the collaboration between hospitals and diagnostic laboratories is expected to accelerate innovation and improve patient outcomes in theranostics.

### By Product Type: Instruments (Largest) vs. Reagents (Fastest-Growing)

In the India theranostics market, the product type segment is primarily composed of instruments, reagents, and software. Among these, instruments hold the largest market share, driven by their critical role in diagnostic procedures. Reagents, while less dominant, are rapidly gaining traction due to their essential function in testing and analysis, making them a significant focus for industry growth.

The growth trends within this segment highlight a robust demand for reagents, driven by advancements in personalized medicine and the rise in chronic diseases which necessitate improved diagnostic capabilities. Instruments continue to evolve, integrating more sophisticated technologies that enhance precision and efficiency. This innovation is critical in staying ahead of competitors and meeting the increasing healthcare demands in India.

Instruments (Dominant) vs. Reagents (Emerging)

Instruments, considered the dominant product type in the India theranostics market, are vital for a wide array of diagnostic applications, including imaging and functional testing. They offer high precision, reliability, and are often developed with advanced technologies that ensure compliance with regulatory standards. On the other hand, reagents are emerging as a key segment due to their indispensable role in facilitating accurate and reliable tests. As the demand for rapid and precise diagnostics increases, reagents are witnessing rapid innovation and adaptation, catering to specific diagnostic needs. This dynamic landscape emphasizes the importance of both instruments and reagents, as they complement each other in enhancing overall diagnostic efficacy.

## Competitive Benchmarking

The theranostics market in India is characterized by a dynamic competitive landscape, driven by advancements in personalized medicine and the increasing prevalence of chronic diseases. Key players such as Roche (CH), Thermo Fisher Scientific (US), and Abbott Laboratories (US) are strategically positioned to leverage their innovative capabilities and extensive product portfolios. Roche (CH) focuses on integrating diagnostics with therapeutics, enhancing patient outcomes through tailored treatment approaches. Meanwhile, Thermo Fisher Scientific (US) emphasizes its commitment to research and development, aiming to expand its offerings in molecular diagnostics and genomic profiling. Abbott Laboratories (US) is actively pursuing partnerships to enhance its diagnostic capabilities, thereby strengthening its market presence and operational focus on point-of-care testing.
The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive innovation and set industry standards, thereby shaping the overall market dynamics.
In September 2025, Roche (CH) announced the launch of a new companion diagnostic test aimed at improving treatment decisions for patients with specific cancer types. This strategic move underscores Roche's commitment to personalized medicine and its focus on integrating diagnostics with therapeutic solutions. The introduction of this test is likely to enhance patient outcomes and solidify Roche's position as a leader in the theranostics space.
In August 2025, Thermo Fisher Scientific (US) expanded its collaboration with a leading Indian biotechnology firm to develop advanced genomic testing solutions. This partnership is strategically important as it allows Thermo Fisher to tap into local expertise and accelerate the development of innovative diagnostic tools tailored to the Indian market. Such collaborations may enhance the company's competitive edge and foster growth in the rapidly evolving theranostics landscape.
In October 2025, Abbott Laboratories (US) unveiled a new digital platform designed to streamline the integration of diagnostic data with treatment protocols. This initiative reflects Abbott's focus on digital transformation and its commitment to improving healthcare delivery. By leveraging technology, Abbott aims to enhance the efficiency of theranostic applications, thereby positioning itself favorably in a market increasingly driven by data and analytics.
As of November 2025, current trends in the theranostics market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostic processes. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on technological advancements and supply chain reliability, moving away from traditional price-based competition. The focus on innovation and the ability to deliver reliable, high-quality solutions will be paramount in defining success in this market.

## Recent News & Developments

The India Theranostics Market has witnessed significant developments, particularly after the COVID-19 pandemic accelerated the demand for personalized medicine and advanced diagnostics. Companies like Roche and Thermo Fisher Scientific are heavily investing in research to develop innovative diagnostics solutions tailored to Indian healthcare needs.

In terms of mergers and acquisitions, there was a notable announcement in September 2023 when Merck & Co. acquired a local biotech firm to expand its capabilities in precision medicine. Similarly, in August 2023, Siemens Healthineers announced a partnership with local hospitals to enhance molecular imaging services, targeting the cancer diagnostic segment.

The market's valuation has been robust, with government initiatives promoting home-grown biopharma innovation, which has been aided by pharmaceutical giants like Pfizer and Novartis expanding their R&D footprints in India. Recent regulatory changes are aimed at fast-tracking approvals for new theranostics products, promoting quicker access to advanced therapies for patients.

## Report Scope

| MARKET SIZE 2024 | 367.04(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 410.24(USD Million) |
| MARKET SIZE 2035 | 1248.28(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.77% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Bristol-Myers Squibb (US), Merck KGaA (DE), Illumina (US), Qiagen (NL), Genomic Health (US) |
| Segments Covered | Application, Technology, End User, Product Type |
| Key Market Opportunities | Integration of artificial intelligence in diagnostic processes enhances precision in the theranostics market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the theranostics market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the India theranostics market in 2024?**
A: The India theranostics market was valued at $367.04 Million in 2024.

**Q: What is the projected market valuation for the India theranostics market by 2035?**
A: The projected valuation for the India theranostics market is $1248.28 Million by 2035.

**Q: What is the expected CAGR for the India theranostics market during the forecast period 2025 - 2035?**
A: The expected CAGR for the India theranostics market during the forecast period 2025 - 2035 is 11.77%.

**Q: Which application segment holds the highest valuation in the India theranostics market?**
A: The oncology application segment holds the highest valuation, with figures ranging from $110.0 Million to $400.0 Million.

**Q: What are the key technology segments in the India theranostics market?**
A: Key technology segments include genomics, proteomics, metabolomics, and biomarkers, with biomarker valuations reaching $135.0 Million to $462.0 Million.

**Q: Who are the leading players in the India theranostics market?**
A: Leading players in the market include Roche, Thermo Fisher Scientific, Abbott Laboratories, and Siemens Healthineers.

**Q: What is the valuation range for the cardiology application segment in the India theranostics market?**
A: The cardiology application segment has a valuation range of $70.0 Million to $200.0 Million.

**Q: Which end user segment is projected to have the highest growth in the India theranostics market?**
A: The diagnostic laboratories end user segment is projected to have the highest growth, with valuations from $150.0 Million to $500.0 Million.

**Q: What product types are included in the India theranostics market?**
A: Product types in the market include instruments, reagents, and software, with reagents valued between $150.0 Million and $500.0 Million.

**Q: How does the growth of the India theranostics market compare to other regions?**
A: While specific regional comparisons are not provided, the robust CAGR of 11.77% suggests a strong growth trajectory for the India theranostics market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-theranostics-market-45578*